Your browser doesn't support javascript.
loading
BCR-ABL Mutation-Guided Therapy for CML Blast Crisis: A Case Report.
Ostendorf, Benjamin N; Nogai, Hendrik; Baldus, Claudia D; Burmeister, Thomas; Arnold, Renate.
Afiliação
  • Ostendorf BN; Charité University Medicine, Department of Hematology, Oncology and Tumor Immunology, Berlin, Germany.
  • Nogai H; Bayer Pharma AG, Berlin, Germany.
  • Baldus CD; Charité University Medicine, Department of Hematology, Oncology and Tumor Immunology, Berlin, Germany.
  • Burmeister T; Charité University Medicine, Department of Hematology, Oncology and Tumor Immunology, Berlin, Germany. ; Labor Berlin, Hematology Division, Tumor Genetics, Berlin, Germany.
  • Arnold R; Charité University Medicine, Department of Hematology, Oncology and Tumor Immunology, Berlin, Germany.
Biomark Insights ; 10(Suppl 3): 25-8, 2015.
Article em En | MEDLINE | ID: mdl-26379418
ABSTRACT
The management of patients with chronic myeloid leukemia (CML) in advanced phases is challenging and requires the consideration of different treatment approaches, including targeted therapy with tyrosine kinase inhibitors, cytotoxic chemotherapy, and allogeneic stem cell transplantation. Here, we present the case of a patient with CML in mixed phenotype blast phase illustrating the integration of these strategies and demonstrating the need for close monitoring of treatment response in order to individually adjust treatment regimens.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2015 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2015 Tipo de documento: Article